Literature DB >> 17941807

In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride.

Bernard McCarey1, Henry Edelhauser.   

Abstract

The effects of two intraocular pressure (IOP)-lowering agents, latanoprost with 0.02% benzylalkonium chloride (BAK) and travoprost Z without BAK, on corneal epithelial permeability, assessed by carboxyfluorescein uptake, were compared in a rabbit cornea model (n = 12). Loss of epithelial tight junctions was measured by ruthenium red uptake with transmission electron microscopy. There was a significant difference between corneal epithelium permeability of rabbits exposed to either travoprost Z or latanoprost preserved with 0.02% BAK (P < 0.0001). There was no difference between untreated controls and those receiving travoprost Z (P = 0.224). Epithelial permeability was significantly increased in the corneas of rabbits exposed to latanoprost in the 3-min drop test (2.16 +/- 1.094 nm/sec) and the 3-min exposure (16.69 +/- 3.15 nm/sec), compared with control or travoprost (P = 0.002), likely due to the presence of a 0.02% concentration of BAK in the latanoprost solutions. There was no detectable loss of epithelial tight junctions in corneas from the control or travoprost Z groups, compared with significant loss in the latanoprost group. Agents such as travoprost Z with an alternative preservative decreased the epithelial toxicity associated with the long-term use of IOP-lowering agents preserved with BAK.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17941807     DOI: 10.1089/jop.2007.0024

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  17 in total

1.  Trans-conjunctival aqueous humor outflow in glaucomatous patients treated with prostaglandin analogues: an in vivo confocal microscopy study.

Authors:  Rodolfo Mastropasqua; Vincenzo Fasanella; Emilio Pedrotti; Manuela Lanzini; Silvio Di Staso; Leonardo Mastropasqua; Luca Agnifili
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-28       Impact factor: 3.117

2.  Corneal neurotoxicity due to topical benzalkonium chloride.

Authors:  Joy Sarkar; Shweta Chaudhary; Abed Namavari; Okan Ozturk; Jin-Hong Chang; Lisette Yco; Snehal Sonawane; Vishakha Khanolkar; Joelle Hallak; Sandeep Jain
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-06       Impact factor: 4.799

3.  Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients.

Authors:  M Figus; M Nardi; P Piaggi; M Sartini; G Guidi; L Martini; S Lazzeri
Journal:  Eye (Lond)       Date:  2014-01-17       Impact factor: 3.775

4.  Cytometric assessment of cytostatic and cytotoxic effects of topical glaucoma medications on human epithelial corneal line cells.

Authors:  Dorota Pozarowska; Piotr Pozarowski; Zbigniew Darzynkiewicz
Journal:  Cytometry B Clin Cytom       Date:  2010-03       Impact factor: 3.058

5.  A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension.

Authors:  David A Godfrey; Lee S Peplinski; Jeanette A Stewart; William C Stewart
Journal:  Clin Ophthalmol       Date:  2009-06-02

6.  Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model.

Authors:  Su Khoh-Reiter; Bart A Jessen
Journal:  BMC Ophthalmol       Date:  2009-07-28       Impact factor: 2.209

7.  Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits.

Authors:  Abayomi B Ogundele; Guangming Li; Joel J Ellis
Journal:  Clin Ophthalmol       Date:  2010-02-18

8.  Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost.

Authors:  Gregory Katz; Clark L Springs; E Randy Craven; Michela Montecchi-Palmer
Journal:  Clin Ophthalmol       Date:  2010-11-03

9.  Aliphatic β-nitroalcohols for therapeutic corneoscleral cross-linking: corneal permeability considerations.

Authors:  Quan Wen; Stephen L Trokel; MiJung Kim; David C Paik
Journal:  Cornea       Date:  2013-02       Impact factor: 2.651

10.  Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay.

Authors:  Hong Liang; Christophe Baudouin; Marie-Odile Faure; Grégory Lambert; Françoise Brignole-Baudouin
Journal:  Mol Vis       Date:  2009-08-25       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.